For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ANR865. CME/MOC/CC/NCPD/CPE/AAPA/IPCE credit will be available until January 16, 2025.
Adapting Our Strategies for Decision-Making in Testing and Treatment of RET-Altered Lung and Thyroid Cancers: A Personalized Learning Journey
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Lilly.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Professor Benjamin Solomon, MBBS, PhD, FRACP, FAHMS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Bristol Myers Squibb; D3 BIO, INC; F. Hoffmann-La Roche AG; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharpe & Dohme; Pfizer; and Takeda Pharmaceutical Company.
Speakers Bureau participant with AstraZeneca; F. Hoffmann-La Roche AG; and Pfizer.
Co-Chair/Planner
Lori J. Wirth, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Blueprint Medicines Corporation; Coherus BioSciences; Eisai Co., Ltd.; Ellipses Pharma Ltd; EMD Serono, Inc.; Exelixis, Inc.; Lilly; Merck & Co., Inc.; and Nested Therapeutics.
Data Safety Monitoring Board for PDS Biotechnology.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
View all episodes
By PVI, PeerView Institute for Medical Education
5
33 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ANR865. CME/MOC/CC/NCPD/CPE/AAPA/IPCE credit will be available until January 16, 2025.
Adapting Our Strategies for Decision-Making in Testing and Treatment of RET-Altered Lung and Thyroid Cancers: A Personalized Learning Journey
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Lilly.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Professor Benjamin Solomon, MBBS, PhD, FRACP, FAHMS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Bristol Myers Squibb; D3 BIO, INC; F. Hoffmann-La Roche AG; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharpe & Dohme; Pfizer; and Takeda Pharmaceutical Company.
Speakers Bureau participant with AstraZeneca; F. Hoffmann-La Roche AG; and Pfizer.
Co-Chair/Planner
Lori J. Wirth, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Blueprint Medicines Corporation; Coherus BioSciences; Eisai Co., Ltd.; Ellipses Pharma Ltd; EMD Serono, Inc.; Exelixis, Inc.; Lilly; Merck & Co., Inc.; and Nested Therapeutics.
Data Safety Monitoring Board for PDS Biotechnology.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
5 Listeners
3 Listeners
3 Listeners
11 Listeners
5 Listeners
28 Listeners
9 Listeners
3 Listeners
2 Listeners
4 Listeners
3 Listeners
5 Listeners
5 Listeners
2 Listeners
0 Listeners
9 Listeners
2 Listeners
12 Listeners
2 Listeners